Tue, Sep 23, 2014, 1:05 PM EDT - U.S. Markets close in 2 hrs 55 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • Nobody is knowing the results from P3. Neither directors from SNSS nor Schinderhannes from Motley Fuul. The trial is well organized and it has a bigger power . You cannot compare this to Celsion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is typical from Motley Fool - i've seen similar, completely unsupported posts from Motley Fool for other solid biotechs. In this case, a) Celsion's lead was thermodox which had very little analyst support and a weak basis for expecting positive results, b) for SNSS the increased enrollment was widely viewed as a positive derisking event for VALOR - not the 2nd worst result as MF asserts (of course, early stop of the trial for positive efficacy would have been more positive, but the increased enrollment signaled it was trending positively and increased the powering which is very helpful).

      SNSS has gone up alot in a very short period of time, on little news, so a pull back on lower volume is unfortunately expected. Seen it before - until we get closer to the readout.

 
SNSS
7.08-0.06(-0.84%)1:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.